semaglutide alcohol use disorder study Once-weekly versus placebo in patients with and comorbid obesity: a randomised, double-blind, placebo-controlled trial Can GLP-1s curb alcohol use?

Pennsylvania Medicaid and Insurance Coverage Pennsylvania Medicaid (MA) covers Saxenda for chronic weight management when prior authorization criteria are met

Not reporting side effects to the clinician

Weight Regain: Like all GLP-1s, stopping the medication will likely result in weight regain

This finding is clinically significant for a patient population like ours in Doral, where the majority of patients present with Fitzpatrick III, IV, and V skin tones

Conclusion: The Evolving Landscape of Weight Loss Treatment The development of GLP-1 medications, dual GIP/GLP-1 agonists, and emerging triple-agonist medications represents one of the most significant advances in obesity medicine in decades

Good Easy to navigate Great communication about shipping and tracking info